For instance, Denlinger et al. (2024) reported an enrichment of PD-1+ CD8+ CAR-T subsets in responders with lymphoma, while Zhang et al. (2024) observed that CAR-T infusion products enriched in CCR7+ early-memory cells and exhibiting low CD39 expression, were predictive of favorable outcomes in chronic lymphocytic leukemia (CLL) [10,11]. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.